Oxacillin for Injection, USP, is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.
The US sales of Oxacillin for the twelve-months ending May 2012 were approximately $29m, according to IMS data.
Oxacillin features the company’s PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors, according to Sagent.
Sagent Pharmaceuticals focuses on developing, manufacturing, sourcing and marketing pharmaceutical products, especially injectable products.